Seegene(096530) said on the 7th that it posted consolidation revenue of 136 billion won and operating profit of 21.6 billion won in the second quarter of this year. Revenue rose 19% from a year earlier, and operating profit increased 586%.
Seegene is shifting its business structure to focus on non-respiratory diagnostics after COVID-19. Human papillomavirus (HPV), sexually transmitted infections, and gastrointestinal infections are representative areas. HPV is transmitted through sexual contact and is cited as a cause of cervical cancer. Sexually transmitted infections can spread to others even without symptoms, driving demand to accurately identify the causative pathogens. Gastrointestinal infections are diagnosed for norovirus, rotavirus, and others.
Seegene's non-respiratory diagnostic revenue increased 23% from a year earlier. HPV diagnostics rose 40%, sexually transmitted infections 21%, and gastrointestinal infections 14%. By region, Europe accounts for 57% of total revenue, followed by Asia (19%), Latin America (12%), Korea (6%), and North America (5%).
Seegene is focusing on Qureca and StarGora, platforms that automate polymerase chain reaction (PCR) testing and analyze results in real time. Qureca runs unmanned from sample input to result analysis. StarGora analyzes PCR tests to help medical staff grasp the trajectory of infectious diseases. Kim Jeong-yong, Seegene's chief financial officer, said, "We will invest in new product development."